A Multi-Center Safety Trial of the Oral Iron Chelator Deferiprone
- 1 June 1998
- journal article
- clinical trial
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 850 (1) , 223-226
- https://doi.org/10.1111/j.1749-6632.1998.tb10478.x
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone)British Journal of Haematology, 1997
- Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron ChelatorsBritish Journal of Haematology, 1995
- Iron-Chelation Therapy with Oral Deferiprone in Patients with Thalassemia MajorNew England Journal of Medicine, 1995
- Arthropathy in thalassaemia patients receiving deferipronePublished by Elsevier ,1994
- Long‐term assessment of efficacy and safety of L1, an oral iron chelator, in transfusion dependent thalassaemia: Indian trialBritish Journal of Haematology, 1992
- Efficacy and possible adverse effects of the oral iron chelator 1,2- dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major [see comments]Blood, 1992
- Development of iron-chelating agents for clinical use [editorial; comment]Blood, 1992
- Antinuclear antibodies in patients taking L1The Lancet, 1991
- Fatal systemic lupus erythematosus in patient taking oral iron chelator L1The Lancet, 1991
- Long‐term trial with the oral iron chelator 1,2‐dimethy1‐3‐hydroxypyrid‐4‐one (L1) II. CLINICAL OBSERVATIONSBritish Journal of Haematology, 1990